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Aim: The signaling pathways involved in the regulation of cardiac GLUT4
translocation/glucose uptake and CD36 translocation/long-chain fatty acid uptake are not
fully understood. We compared in heart/muscle-specific PKC-λ knockout mice the roles
of atypical PKCs (PKC-ζ and PKC-λ) in regulating cardiac glucose and fatty acid uptake.
Results: Neither insulin-stimulated nor AMPK-mediated glucose and fatty acid uptake
were inhibited upon genetic PKC-λ ablation in cardiomyocytes. In contrast, myristoylated
PKC-ζ pseudosubstrate inhibited both insulin-stimulated and AMPK-mediated glucose
and fatty acid uptake by >80% in both wild-type and PKC-λ-knockout cardiomyocytes. In
PKC-λ knockout cardiomyocytes, PKC-ζ is the sole remaining atypical PKC isoform, and
its expression level is not different from wild-type cardiomyocytes, in which it contributes
to 29% and 17% of total atypical PKC expression and phosphorylation, respectively.
Conclusion: Taken together, atypical PKCs are necessary for insulin-stimulated and
AMPK-mediated glucose uptake into the heart, as well as for insulin-stimulated and
AMPK-mediated fatty acid uptake. However, the residual PKC-ζ activity in PKC-λ-knockout
cardiomyocytes is sufficient to allow optimal stimulation of glucose and fatty acid uptake,
indicating that atypical PKCs are necessary but not rate-limiting in the regulation of cardiac
substrate uptake and that PKC-λ and PKC-ζ have interchangeable functions in these
processes.
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INTRODUCTION
Glucose and long-chain fatty acids are the most important car-
diac substrates. Both substrates are efficiently extracted from the
interstitial space by substrate specific sarcolemmal transporters.
GLUT4 is well-known to be the main cardiac glucose trans-
porter. It is also well-established that GLUT4 translocation from
recycling endosomes to the plasma membrane accounts for stim-
ulation of cardiac glucose uptake upon physiological stimuli,
especially increased contractile activity and increased circulat-
ing levels of insulin (Sevilla et al., 1997; Glatz et al., 2010).
With respect to fatty acid uptake, the heart expresses several dis-
tinct fatty acid transporters, most notably CD36 and members
of the FATP family (FATP1 and 6) (Doege and Stahl, 2006; Glatz
et al., 2010). Similar to GLUT4, in the heart also CD36 translo-
cates from intracellular stores to the sarcolemma upon insulin
and contraction stimulation (Glatz et al., 2010). Importantly, in
Abbreviations: AMPK, AMP-activated protein kinase; aPKC, atypical protein
kinase C; AS160, Akt substrate 160; CD36, fatty acid translocase CD36; GAPDH,
glyceraldehydes-3-phosphate dehydrogenase; GLUT4, glucose transporter 4; PKC,
protein kinase C; VAMP2, vesicle-associated membrane protein-2.
CD36-knockout mice, stimulus-induced fatty acid uptake was
completely abrogated, emphasizing a key role of CD36 in the
regulation of cardiac fatty acid fluxes (Habets et al., 2007). In con-
trast, the quantitative importance of the FATPs in cardiac fatty
acid uptake is not yet clear.
The signaling cascades involved in the regulation of GLUT4
translocation and glucose uptake have been topic of intensive
research, whereas the investigation of signaling enzymes involved
in the regulation of CD36 translocation and fatty acid uptake has
only recently been initiated (Glatz et al., 2010). Strikingly, the sig-
naling enzymes found to be involved in the regulation of CD36
translocation and fatty acid uptake in the heart are also known to
be essential in the regulation of GLUT4 translocation and glucose
uptake. Namely, the PI3K—Akt/PKB insulin signaling pathway
mediates insulin-induced GLUT4 translocation as well as insulin-
induced CD36 translocation in cardiomyocytes (Luiken et al.,
2002, 2004). Our recent data concerning the ability of myristoy-
lated PKC-ζ pseudosubstrate to inhibit insulin-stimulated glucose
uptake and fatty acid uptake in cardiomyocytes (Luiken et al.,
2009) also indicate that the atypical PKC isoform PKC-ζ is
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essential for insulin-induced translocation of GLUT4 and CD36,
respectively. However, given that PKC-ζ was already fully active
in cardiomyocytes under basal conditions and was not further
activated by insulin indicated that PKC-ζ has a permissive but
not a regulatory role in insulin-stimulated glucose and fatty acid
uptake.
With respect to contraction-induced GLUT4 translocation as
well as contraction-induced CD36 translocation in cardiomy-
ocytes, both LKB1 and AMPKα2 have been shown to be essential
(Habets et al., 2009). Interestingly, recent studies in rat (Chen
et al., 2002; Sajan et al., 2010) and human (Richter et al.,
2004) skeletal muscle showed that (1) treadmill exercise activated
hindlimb PKC-ζ, and that (2) stimulation of GLUT4 transloca-
tion and glucose uptake by the AMPK activating agent AICAR
was inhibited by myristoylated PKC-ζ pseudosubstrate, together
indicating that this atypical PKC operates in the same signaling
cascade as AMPK to stimulate GLUT4 translocation and glucose
uptake in response to contraction.Whether PKC-ζ is also involved
in AMPK-mediated CD36 translocation and fatty acid uptake in
cardiomyocytes is not known yet.
In rodent muscle, two atypical PKC isoforms occur, i.e., PKC-ζ
and PKC-λ. Whereas PKC-ζ is the predominant atypical PKC
isoform in rat muscle tissues (Pucéat et al., 1994; Shizukuda
and Buttrick, 2002), PKC-λ is the major representative of the
atypical PKCs in mouse muscle tissues (Akimoto et al., 1994).
Therefore, to study the role of atypical PKCs in insulin-stimulated
glucose uptake into skeletal muscle, heart/muscle-specific PKC-λ
knockout mice were generated (Farese et al., 2007). This indeed
resulted in a large decrease in overall atypical PKC activity inmus-
cle concomitant with a reduction of insulin-stimulated glucose
uptake, confirming that atypical PKCs are essential in this process
(Farese et al., 2007). These heart/muscle-specific PKC-λ knockout
mice exhibited whole body insulin resistance, hyperinsulinemia,
abdominal obesity, and several other lipid abnormalities, indicat-
ing that a specific defect in muscle atypical PKCs is sufficient to
induce hallmark features of type-2 diabetes and the metabolic
syndrome (Farese et al., 2007).
We used cardiomyocytes from these heart/muscle-specific
PKC-λ knockout mice to study (1) whether PKC-λ and PKC-ζ
play similar roles in insulin-stimulated glucose and fatty acid
uptake into cardiomyocytes from heart/muscle-specific PKC-λ
knockout mice, and to study (2) the role of atypical PKCs in
AMPK-mediated glucose and fatty acid uptake.
MATERIALS AND METHODS
MATERIALS
[1−14C]palmitic acid, 2-deoxy-D-[1−3H]glucose were from GE
Healthcare (Piscataway, NJ, USA). BSA (fraction V, essen-
tially fatty acid free), phloretin and insulin were from Sigma
(St. Louis, MO). Liberase blendzyme 1 was from Roche
Diagnostics (Indianapolis, IN). Antibodies against CD36 and
GLUT4 were from Chemicon International Inc. (Temecula,
USA). The rabbit polyclonal antibody against PKC-λ and PKC-ζ
(C-20) was from Transduction Laboratories (Sparks, MD, USA).
The antibody against phosphorylated acetyl-CoA carboxylase
(ACC) (Ser79) was from Upstate (Dundee, UK). Anti-phospho-
Akt (Ser473), anti-phospho-(Ser/Thr) Akt substrate (PAS), and
anti-phospho-PKC-ζ (Thr410/403) antibodies were from Cell
Signaling Technology (Beverly, MA, USA).
ANIMALS
Embryonic stem cells containing a floxed PKC-λ allele (with
loxP sites flanking exon 110-233) were used to generate C57Bl/6
mice with germline-transmitted floxed PKC-λ. These mice were
crossed with mice harboring a muscle creatine kinase-driven Cre
recombinase transgene to generate heterozygous and homozy-
gous heart/muscle-specific PKC-λ knockout mice and various
littermates (Farese et al., 2007). The mice were bred in the
Muscle Research Centre, University of Copenhagen, according to
the guidelines of that institution. After shipment to Maastricht,
experiments were performed according to the guidelines of the
Experimental Animal Committee of Maastricht University.
ISOLATION AND PRE-INCUBATION OF MOUSE
CARDIOMYOCYTES
Mouse cardiomyocytes were isolated from hearts of male
homozygous heart/muscle-specific PKC-λ knockout mice and
their wild-type male littermates (mice, 6–8 months of age) using
a Langendorff perfusion system as previously described (Habets
et al., 2007). Cell suspensions (2.0ml; 5–10mg wet mass/ml; via-
bility 60–80%) were pre-incubated in capped incubation vials
either with 0.35% DMSO (Ctrl), 100 nmol/l insulin or 1μM
oligomycin for 20min at 37◦C under continuous shaking before
subsequentmeasurements weremade.Myristoylated PKC-ζ pseu-
dosubstrate (50μM) was added 20min prior to addition of
insulin or oligomycin.
PROTEIN EXPRESSION AND PHOSPHORYLATION
Pellets of stimulated cell suspensions were dissolved in sample
buffer, as previously described (Habets et al., 2007), and subjected
to SDS-polyacrylamide gel electrophoresis, followed by Western
blotting for the detection of GLUT4, CD36, VAMP2 andGAPDH,
and of phospho-AS160 (PAS antibody), phospho-ACC (Ser79),
phospho-Akt (Ser473) by applying the antibodies according to
the manufacturer’s instructions.
PALMITATE AND DEOXYGLUCOSE UPTAKE
For palmitate and deoxyglucose uptake, 0.5ml of a mixture
of [1−14C]palmitate/BSA complex and [1−3H]deoxyglucose
was added to pre-incubated cell suspensions (final concentra-
tions: palmitate, 100μmol/l; deoxyglucose, 100μmol/l; palmi-
tate/BSA ratio 0.3). The rate of uptake of 14C-palmitate and of
3H-deoxyglucose in a 3-min incubation, i.e., within the initial
uptake phase, was determined as previously described (Habets
et al., 2007). The uptake was terminated by adding of an ice-cold
stop solution containing 0.2mmol/l phloretin, followed by wash-
ing the cells twice for 2min at 45 g and assessing the radioactivity
in the pellet.
QUANTITATIVE GENE EXPRESSION
Total RNA was isolated from cardiomyocytes using Tri-Reagent
(Sigma). Total RNA (500 ng) was reverse transcribed using the
iScript™ cDNA synthesis kit (Bio-Rad). Quantitative PCR was
performed on the MyiQ Single Color Real-Time PCR Detection
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System (BioRad) using 10 ng cDNA, 300 nM of each primer
and IQ SYBR Green Supermix (BioRad) in a total volume of
20μl. Primer sequences of PKC-ζ are available upon request.
Cyclophilin A was used as housekeeping gene.
DATA PRESENTATION AND STATISTICS
All data are presented as means ± S.E.M. for the indicated num-
ber of cardiomyocyte preparations. Statistical difference between
means was analyzed by the paired Student’s t-test. P ≤ 0.05 was
considered significant.
RESULTS
CHARACTERIZATION OF CARDIOMYOCYTES FROM PKC-λ
KNOCKOUT MICE
Hearts from heart/muscle-specific PKC-λ knockout mice were
previously controlled for proper deletion of PKC-λ (Farese
et al., 2007) using a rabbit polyclonal antibody directed against
a peptide spanning residues 184-234 of the PKC-λ protein.
This PKC-λ-specific antibody does not recognize PKC-ζ (Kovac
et al., 2007). Indeed protein expression of PKC-λ appeared
largely absent in hearts from heart/muscle-specific PKC-λ
knockout mice (Farese et al., 2007). PKC-ζ expression was
readily detectable in wild-type mouse heart. Moreover, its mRNA
content was unchanged in PKC-λ knockout heart (Figure 1).
This observation is in line with previous observations in hearts
from PKC-λ knockout showing no change in protein expression
levels of PKC-ζ (Farese et al., 2007). A commercailly available
antibody (Santa Cruz–C20) has been commonly used to detect
PKC-λ (Farese et al., 2007; Luiken et al., 2009). This rabbit
polyclonal antibody recognizes the C-terminus of atypical
PKCs, which is identical for PKC-λ and PKC-ζ. Therefore, this
antibody cannot discriminate between each of these atypical
PKC isoforms (Farese et al., 2007). Using this antibody, it was
observed that total atypical PKC expression was reduced by 79%
(Figure 1). When using an antibody recognizing the Thr410/403
phosphomotif within the activation loop, which is also shared
by both PKC-λ and PKC-ζ, total atypical PKC activation loop
phosphorylation was reduced by 87% (Figure 1).
Expression of GLUT4 and CD36 was similar in wild-type and
PKC-λ knockout cardiomyocytes (Figure 2). This indicates that
the potential capacity for fatty acid and glucose transport in car-
diomyocytes is not altered due to heart/muscle-specific knockout
of PKC-λ.
Insulin signaling through the Akt/PKB–AS160 axis was not
altered due to the genetic ablation of PKC-λ in cardiomyocytes
because insulin induced a similar increase in Akt/PKB-Ser473
phosphorylation and in AS160 phosphorylation at the PAS motif
in wild-type and PKC-λ knockout cardiomyocytes (Figure 2).
We used the mitochondrial F1F0-ATPase inhibitor oligomycin
to activate AMPK signaling because oligomycin-stimulated glu-
cose and fatty acid uptake is entirely mediated through AMPK
(Habets et al., 2009). In addition to insulin signaling, AMPK sig-
naling in cardiomyocytes was not affected by ablation of PKC-λ,
because oligomycin-induced ACC-Ser79 phosphorylation was
not different between wild-type and knockout cardiomyocytes
(Figure 2).
VAMP2 has been reported to be a direct substrate of atypi-
cal PKCs, as shown in adipocytes (Braiman et al., 2001). Because
VAMP2 is functioning as a v-SNARE in GLUT4 translocation in
adipocytes (Olson et al., 1997) and muscle (Sevilla et al., 1997),
an upregulation in VAMP2 expression could serve as a compen-
satory mechanism to maintain GLUT4 translocation. However,
VAMP2 was not found to be upregulated in PKC-λ knockout car-
diomyocytes (Figure 2), excluding the occurrence of this possible
FIGURE 1 | Expression of PKC-ζ, and expression and phosphorylation of
total atypical PKC in hearts fromwild-type andmuscle-specific
PKC-λ-knockoutmice. Heart homogenates from wild-type (WT) and
PKC-λ-knockout (KO) mice were used for PCR analysis of PKC-ζ (left graph) and
Westerndetectionof total atypical PKCexpression andphosphorylation (middle
andrightgraph). IncaseofWesterndetection, representativeblotsaredisplayed
above each graph. Data are means ± SEM for six experiments carried out with
different heart homogenates. ∗Significantly different from WT (P < 0.05).
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FIGURE 2 | Expression of GLUT4, CD36, and VAMP2 in cardiomyocytes
from wild-type and muscle-specific PKC-λ-knockout mice, and the
effects of insulin and oligomycin treatment on phosphorylation of Akt,
AS160, and ACC. Wild-type (WT) and PKC-λ-knockout (KO) cardiomyocytes
were used to determine GLUT4, CD36, VAMP2, and GAPDH (loading control)
expression, and after incubation for 20min in the absence (Ctrl) or presence
of 100 nM insulin (Ins) or 1μM oligomycin (Oli) for assessment of
phospho-Akt (Ser473), phospho-ACC (Ser79), and phospho-AS160 by
Western blotting. In case of VAMP2, a sample from homogenized rat brain
of identical protein content was used as a positive control on the expression
of this protein. A representative Western blot is presented out of five
experiments with different cardiomyocyte preparations.
compensatory mechanism. Taken together, possible alterations
in substrate uptake due to the ablation of PKC-λ in cardiomy-
ocytes cannot be ascribed to compensatory changes in any of the
parameters studied.
EFFECT OF PKC-λ ABLATION ON GLUCOSE AND FATTY ACID UPTAKE
In agreement with our previous observations in wild-type car-
diomyocytes (Habets et al., 2009), glucose uptake was stimulated
by 4.3-fold and 3.3-fold in wild-type cardiomyocytes upon treat-
ment with insulin or oligomycin, respectively, and fatty acid
uptake by 1.2-fold and 1.6-fold (Figure 3). Surprisingly, the mag-
nitude of stimulation of glucose and fatty acid uptake in PKC-λ
knockout cardiomyocytes was comparable to that observed in
wild-type cardiomyocytes (Figure 3). However, when wild-type
or PKC-λ knockout cardiomyocytes were pre-incubated with
myristoylated PKC-ζ pseudosubstrate, insulin- or oligomycin-
stimulated glucose uptake and insulin- or oligomycin-stimulated
fatty acid uptake were largely (>80%) or almost fully reduced
to basal uptake levels (Figure 3). Treatment with myristoylated
PKC-ζ pseudosubstrate did not affect basal fatty acid or glucose
uptake (Figure 3).
DISCUSSION
In a recent study, we observed that in rat cardiomyocytes PKC-ζ
is essential for insulin-stimulated GLUT4 translocation/glucose
uptake and insulin-stimulated CD36 translocation/fatty acid
uptake (Luiken et al., 2009). However, the role of PKC-ζ in these
processes was proposed to bemerely permissive because this atyp-
ical PKC isoform was already fully active in the heart under
basal conditions and not further activated by insulin treatment.
In the present study, we further examined the role of atypical
PKCs in insulin-stimulated glucose and fatty acid uptake, and
explored the role of atypical PKCs in AMPK-mediated glucose
and fatty acid uptake in heart/muscle-specific PKC-λ knockout
mice. Using cardiomyocytes from this mouse model in combina-
tion with the specific atypical PKC inhibitor myristoyted PKC-ζ
pseudosubstrate, the following major observations were made:
(1) atypical PKCs are essential not only for insulin-stimulated glu-
cose and fatty acid uptake but also for AMPK-mediated glucose
and fatty acid uptake, and (2) the residual atypical PKC-ζ isoform
in PKC-λ knockout cardiomyocytes is sufficient to allow max-
imal insulin-stimulated and AMPK-mediated glucose and fatty
acid uptake.
ATYPICAL PKCs ARE ESSENTIAL FOR INSULIN-STIMULATED
AND AMPK-MEDIATED GLUCOSE AND FATTY ACID UPTAKE
Pharmacological inhibition of total atypical PKC activity,
using myristoylated PKC-ζ pseudosubstrate, rather than genetic
ablation of the major mouse heart atypical PKC isoform
PKC-λ, revealed that atypical PKCs are necessary for both
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FIGURE 3 | Effects of insulin and oligomycin stimulation on
deoxyglucose and palmitate uptake in cardiomyocytes from
wild-type and muscle-specific PKC-λ-knockout mice. Wild-type
(WT) and PKC-λ-knockout cardiomyocytes were preincubated in the
absence (basal) or presence of 50μM myristoylated PKC-ζ
pseudosubstrate (myr-ζ-PS), and subsequently incubated for 20min in
the absence (Ctrl) or presence of 100 nM insulin (Ins) or 1μM
oligomycin (Oli), whereafter uptake rates of 3H-deoxyglucose and
14C-palmitate were measured. Data are means ± SEM for six
experiments carried out with different cardiomyocyte preparations.
∗Significantly different from Ctrl (P < 0.05). ∧Significantly different
from corresponding basal (P < 0.05).
insulin-stimulated and AMPK-mediated glucose and fatty acid
uptake into the heart. The myristoylated PKC-ζ pseudosub-
strate is known to inhibit both PKC-ζ and PKC-λ because the
sequence of this synthetic oligopeptide is present in the pseu-
dosubstrate region of both isoforms (Akimoto et al., 1994),
and is known to effectively inhibit total atypical PKC activ-
ity in cellular systems at 10–100μM concentrations (e.g., see
Standaert et al., 1997). In agreement with these findings, we
have recently shown that in rat cardiomyocytes 50μM myris-
toylated PKC-ζ pseudosubstrate largely inhibited total atypical
PKC activity in rat cardiomyocytes (Luiken et al., 2009). At this
concentration the pseudosubstrate does not cause any inhibition
of Akt phosphorylation (Luiken et al., 2009) indicating that its
effect is not due to inhibition of the canonical insulin signaling
pathway. Importantly, 50μM myristoylated PKC-ζ pseudosub-
strate completely inhibited insulin-stimulated glucose and fatty
acid uptake into rat cardiomyocytes (Luiken et al., 2009), indi-
cating that atypical PKCs are involved in both processes. For
insulin-stimulated fatty acid uptake this was a novel finding but
for insulin-stimulated glucose uptake this has been known for
more than a decade, at least in adipocytes (Standaert et al.,
1997).
Less research has been done to employ the myristoylated
PKC-ζ pseudosubstrate in AMPK-mediated glucose uptake, and
indeed this synthetic peptide revealed the involvement of atypical
PKCs in this process, at least in L6 myotubes (Chen et al., 2002;
Sajan et al., 2010). Hence, ours is the first study that shows that
atypical PKCs are necessary for AMPK-stimulated glucose uptake
into a cardiac cellular model system and for AMPK-stimulated
fatty acid uptake into any cell type or tissue.
Earlier, we established in rat cardiomyocytes (Luiken et al.,
2002) and in mouse cardiomyocytes (Habets et al., 2009) that
enhancement of glucose uptake and fatty acid uptake upon
insulin or AMPK stimulation is of similar magnitude as the
increase in cell surface content of GLUT4 and of CD36, respec-
tively, indicating that translocation of both transporters accounts
for the increase in uptake of both substrates. Moreover, in the case
of fatty acids, we have shown that the increase in uptake of this
substrate in response to insulin stimulation (data not shown) or
AMPK stimulation (Habets et al., 2009) is absent in cardiomy-
ocytes from CD36 knockout mice, implicating the involvement
of CD36 in insulin-stimulated and in AMPK-mediated fatty acid
uptake. In addition, we have shown that inhibition of atypi-
cal PKCs by staurosporin completely blocks insulin-stimulated
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glucose and fatty acid uptake, and also insulin-stimulated GLUT4
and CD36 translocation (Luiken et al., 2009). Hence, it may be
concluded that the mechanism of involvement of atypical PKCs
in stimulation of glucose and fatty acid uptake encompasses the
translocation of GLUT4 and CD36.
PKC-ζ IN PKC-λ KNOCKOUT CARDIOMYOCYTES IS SUFFICIENT
FOR OPTIMAL STIMULATION OF CARDIAC SUBSTRATE UPTAKE
Remarkably, the abilty of the myristoylated PKC-ζ pseudosub-
strate to inhibit insulin-stimulated or AMPK-mediated substrate
uptake into cardiomyocytes is in sharp contrast with the inability
of genetic PKC-λ ablation to block these processes. The only plau-
sible explanation to integrate these findings is to assume that in
PKC-λ-knockout cardiomyocytes there is sufficient atypical PKC
activity left to sustain maximal GLUT4 and CD36 translocation.
Still, in the heart of heart/muscle-specific PKC-λ-knockout mice
PKC-λ is largely absent (Farese et al., 2007). Importantly, our
present results and those of Farese show that in PKC-λ-knockout
cardiomyocytes (Figure 1) or in PKC-λ-knockout hearts (Farese
et al., 2007), PKC-ζ is still present, and, moreover, the expres-
sion of this atypical PKC isoform at the mRNA level (Figure 1)
or at the protein level (Farese et al., 2007) is not changed in
comparison to wild-type cardiomyocytes or wild-type hearts. It
is obvious that the residual total PKC expression (21%) and
phosphorylation (13%) in PKC-λ-knockout cardiomyocytes (see
Figure 1) can be completely ascribed to PKC-ζ. Because PKC-ζ
expression is not different in wild-type and PKC-λ-knockout car-
diomyocytes, it can be deduced that in these wild-type myocytes
PKC-ζ presents 13–21% of total atypical PKC amount or capac-
ity. Upon genetic deletion of PKC-λ, this remaining PKC-ζ is still
sufficient for optimal regulation of substrate uptake in the heart.
This implies therefore that (1) there is a redundancy/excess total
atypical PKC capacity of at least 5-fold in relation to insulin-
stimulated or AMPK-mediated glucose and fatty acid uptake into
FIGURE 4 | Schematic presentation of the putative permissive role of
atypical protein kinase C (isoforms ζ/λ) in GLUT4 and CD36
translocation in the heart. Upon binding to its receptor at the cell surface,
insulin sequentially activates insulin-receptor substrate 2 (IRS2) and PI3K,
resulting in the production of PIP3. Beyond PI3K, the insulin signal is split into
two parallel branches. PIP3 binds to both Akt/PKB and PKC-ζ/λ. In case of
Akt/PKB this results in the activation and subsequent phosphorylation of
AS160. In case of PKC-ζ/λ this does not result in further activation because
the basally high levels of phosphatidic acid (PA) in the heart impose PKC-ζ/λ
to be already bound to endosomal membranes in the absence of insulin
treatment. Hence, PKC-ζ/λ maintains the endosomal membranes in a
pre-active state, waiting for the insulin signal through activation of Akt/PKB
and AS160 to complete the final stages in the budding of GLUT4- and
CD36-containing vesicles for translocation to the sarcolemma. Upon
contraction-induced activation of AMP-activated protein kinase (AMPK), a
signaling cascade also involving ERK and PDK1, similarly will activate AS160
but not further activate PKC-ζ/λ. In agreement with the dependence of
insulin-stimulated GLUT4- and CD36 translocation of PKC-ζ/λ, these
processes will be subjected to inhibition by myristoylated PKC-ζ
pseudosubstrate (ζ-PS). (Modified from Luiken et al., 2009).
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cardiomyocytes, so to propose that atypical PKCs are necessary
but not rate-limiting in the regulation of cardiac substrate uptake,
and (2) that PKC-λ and PKC-ζ can substitute for each other in the
regulation of cardiac substrate uptake.
CONCLUDING REMARKS
In the present study we have shown that atypical PKCs are
necessary but not rate-limiting in the regulation of cardiac sub-
strate uptake (summarized in Figure 4). It should be stressed
that this conclusion may be tissue-specific. Namely, as men-
tioned in the “Introduction,” in PKC-λ-deficient skeletal muscle
insulin-stimulated GLUT4 translocation and glucose uptake were
largely abolished (Farese et al., 2007). Yet, in PKC-λ deficient
heart insulin-stimulated glucose uptake was fully normal, as
were AMPK-mediated glucose uptake and insulin-stimulated and
AMPK-mediated fatty acid uptake (present study). As a result,
atypical PKCs appear to be necessary for the regulation of sub-
strate uptake in both heart and skeletal muscle. However, only
in the heart is there an overcapacity of atypical PKC isoforms in
relation to insulin/oligomycin-stimulated glucose and fatty acid
uptake, while in skeletal muscle the genetic ablation of PKC-λ
is apparently rate-limiting for insulin-stimulated glucose uptake.
Since the expression of PKC-λ and PKC-ζ is comparable between
heart and muscle (Farese et al., 2007, and own data, not shown)
it is difficult to explain the differential involvement of atypi-
cal PKCs in the regulation of glucose uptake. Since Farese et al.
(2007) did not investigate the regulation of fatty acid uptake in
PKC-λ-deficient skeletal muscle it cannot be deduced whether
insulin-stimulated or AMPK-mediated fatty acid uptake would be
completely blocked in this tissue by genetic PKC-λ ablation. Thus,
whether there is tissue-specificity with respect to the involve-
ment of atypical PKCs in regulating fatty acid uptake remains
unknown.
We can only speculate as to the functional significance for
an overcapacity of atypical PKCs in the relation to regulation of
cardiac substrate uptake. However, it should be noted that in the
heart atypical PKCs are involved in various other biological func-
tions besides regulation of substrate uptake, such as the regulation
of cell growth, polarity, and apoptosis (Shizukuda and Buttrick,
2002; Liu et al., 2006). It is possible that these processes require
a much greater capacity of atypical PKCs than is needed for the
regulation of substrate uptake.
Finally, in the healthy heart there is an optimal balance
between glucose and fatty acid uptake in order to sustain proper
mechanical function. In various cardiac diseases this substrate
balance is disturbed, which could result in impaired func-
tioning. Therapies aimed at normalization of cardiac substrate
metabolism through selective translocation of either GLUT4 or
CD36 have been proposed to protect the diseased heart against
loss of function (Glatz et al., 2006). Therefore, it became of inter-
est to search for signaling and trafficking proteins specifically
dedicated to either GLUT4 or CD36 translocation, because these
proteins would offer attractive targets to modulate substrate pref-
erence. However, atypical PKCs would not provide such target.
First, atypical PKCs are similarly involved in the regulation of glu-
cose uptake and fatty acid uptake by the heart, and therefore these
PKC isoforms lack the ability to discriminate between both pro-
cesses. Second, since PKCs do not present a rate-limiting step, a
potential pharmacological activation or partial inhibition should
have little, if any, effect on cardiac glucose and fatty acid fluxes.
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